This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer disease and also with decreased affinity for fibrin-binding. The protein encoded by this gene converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. This gene's proprotein is cleaved at a Lys-Ile bond by plasmin to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor.
^Nagai M, Hiramatsu R, Kaneda T, Hayasuke N, Arimura H, Nishida M, Suyama T (Dec 1985). "Molecular cloning of cDNA coding for human preprourokinase". Gene36 (1-2): 183–8. doi:10.1016/0378-1119(85)90084-8. PMID2415429.
^Geiger, M; Huber K; Wojta J; Stingl L; Espana F; Griffin J H; Binder B R (Aug 1989). "Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo". Blood (UNITED STATES) 74 (2): 722–8. ISSN0006-4971. PMID2752144.
Ploug M, Gårdsvoll H, Jørgensen TJ, et al. (2002). "Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.". Biochem. Soc. Trans.30 (2): 177–83. doi:10.1042/BST0300177. PMID12023847.
Alfano M, Sidenius N, Blasi F, Poli G (2004). "The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.". J. Leukoc. Biol.74 (5): 750–6. doi:10.1189/jlb.0403176. PMID12960238.
Harbeck N, Kates RE, Gauger K, et al. (2004). "Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.". Thromb. Haemost.91 (3): 450–6. doi:10.1160/TH03-12-0798. PMID14983219.
Gilabert-Estelles J, Ramon LA, España F, et al. (2006). "Expression of the fibrinolytic components in endometriosis.". Pathophysiol. Haemost. Thromb.35 (1-2): 136–40. doi:10.1159/000093556. PMID16855359.